Discover 3,133 paid clinical trials in Houston, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Houston is home to world-renowned medical centers offering a variety of trials targeting conditions such as cancer, heart disease, diabetes, and Alzheimer’s. Healthy volunteers interested in paid research opportunities, as well as individuals in need of trials for specific conditions, can participate in these studies to access cutting-edge treatments and contribute to the development of innovative therapies.
Filter
2
Filter results
Results: 3,133
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
for
Geographic Atrophy (GA),
Location: Bellaire TX, Katy TX, The Woodlands TX, Beaumont TX,
Sponsor: ONL Therapeutics
Sex: All
Age: 55+
Code: NCT06659445
Phase 2, Recruiting
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
for
Prostate Cancer
Location: Houston TX, Ann Arbor MI, London, Toronto, Ottawa,
Sponsor: University of British Columbia
Sex: Male
Age: 18+
Code: NCT04812366
Phase 2, Recruiting
Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer
for
Breast Cancer
Location: Houston TX, San Antonio TX, Jacksonville FL,
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT07076485
Phase 2, Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
for
Non-Small-Cell Lung Cancer,
Location: Houston TX, Dallas TX, Aurora CO, Chicago IL,
Sponsor: ArriVent BioPharma, Inc.
Sex: All
Age: 18+
Code: NCT07185997
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Interactive Design of Patient-Specific Molds for Tissue Shaping
for
Mastectomy
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT06711965
Recruiting
Registry Trial and Needs Assessment of Patients With Young-onset Lung Cancer: Impact of a Dedicated Care Program on Patient Experience and Outcomes
for
Lung Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18 - 50
Code: NCT07220096
Recruiting
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
for
Hidradenitis Suppurativa
Location: Webster TX, San Antonio TX, Fort Smith AR,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18 - 70+
Code: NCT07665437
Phase 3, Recruiting
Evaluation of a Novel Optical Microscope With a Deep Depth of Field (DeepDOF) to Provide Histologic-quality Images on Cervical Biopsies and Loop Electrosurgical Excision Procedure (LEEP) Specimens at the Point-of-care
for
Cervical Cancer, HIV
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: Female
Age: 25 - 49
Code: NCT06850402
Recruiting
Non-invasive Prediction of EArly Cardiac rEjection
A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome
for
Rett Syndrome
Location: Houston TX, Irving TX, Little Rock AR, Atlanta GA,
Sponsor: UCB BIOSCIENCES, Inc.
Sex: All
Age: 5 - 35
Code: NCT07503444
Phase 3, Recruiting
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
for
Acute Myeloid Leukemia (AML)
Location: Houston TX, Austin TX, San Antonio TX, Dallas TX,
Sponsor: Kura Oncology, Inc.
Sex: All
Age: 18+
Code: NCT07007312
Phase 3, Recruiting
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer